Stephanie Blank is an Oncology physician affiliated with Mount Sinai Health System. OpenAlex indexes 106 publications with 793 citations (h-index 10); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
160 E 34th St
4th Fl.
New York, NY 100164750
Telephone
212-731-5345Registry record last updated 8 Jul 2007.
Clinical trials
- A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
Sponsor: Tigris Pharmaceuticals
- Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Sponsor: NYU Langone Health
- Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BioNTech SEProgram year20251 payment
- GlaxoSmithKline, LLC.Program year20221 payment
- Intuitive Surgical, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Comparative Modeling for the Prevention and Control of Uterine Cancer
Columbia University Health Sciences
FY2025$630,059U01CA265739 - Comparative Modeling for the Prevention and Control of Uterine Cancer
Columbia University Health Sciences
FY2024$803,402U01CA265739 - Comparative Modeling for the Prevention and Control of Uterine Cancer
Columbia University Health Sciences
FY2023$856,073U01CA265739
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors
Journal for ImmunoTherapy of Cancer
2025 - Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Cancer Epidemiology Biomarkers & Prevention
2025 - Trends in uterine cancer incidence and mortality: insights from a natural history model
JNCI Journal of the National Cancer Institute
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Desnick, PhD, MD
Mount Sinai Health System
Mathew Williams, MD
Mount Sinai Health System
Ashutosh Tewari, MD
Mount Sinai Health System
Sahil Khera, MD, MPH
Mount Sinai Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”